Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:NAMS NYSE:OGN NASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$22.27-0.2%$18.49$9.96▼$23.15$3.57B2.072.83 million shs2.82 million shsNAMSNewAmsterdam Pharma$29.64-3.0%$32.80$21.14▼$42.21$3.57B0.08945,305 shs1.09 million shsOGNOrganon & Co.$13.53-0.3%$13.46$5.69▼$13.60$3.55B1.542.42 million shs3.82 million shsPHARPharming Group$12.61-4.3%$13.12$9.54▼$21.34$932.15M-0.045,866 shs5,373 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-0.18%-2.84%+15.15%+57.50%+104.88%NAMSNewAmsterdam Pharma-2.98%-6.44%-9.09%-0.27%+23.60%OGNOrganon & Co.-0.37%0.00%+0.45%+19.29%+34.08%PHARPharming Group-4.29%-6.42%-2.89%-24.52%+22.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$22.27-0.2%$18.49$9.96▼$23.15$3.57B2.072.83 million shs2.82 million shsNAMSNewAmsterdam Pharma$29.64-3.0%$32.80$21.14▼$42.21$3.57B0.08945,305 shs1.09 million shsOGNOrganon & Co.$13.53-0.3%$13.46$5.69▼$13.60$3.55B1.542.42 million shs3.82 million shsPHARPharming Group$12.61-4.3%$13.12$9.54▼$21.34$932.15M-0.045,866 shs5,373 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-0.18%-2.84%+15.15%+57.50%+104.88%NAMSNewAmsterdam Pharma-2.98%-6.44%-9.09%-0.27%+23.60%OGNOrganon & Co.-0.37%0.00%+0.45%+19.29%+34.08%PHARPharming Group-4.29%-6.42%-2.89%-24.52%+22.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.57Moderate Buy$20.83-6.45% DownsideNAMSNewAmsterdam Pharma 2.93Moderate Buy$49.4266.72% UpsideOGNOrganon & Co. 1.71Reduce$11.40-15.71% DownsidePHARPharming Group 2.40Hold$38.33204.11% UpsideCurrent Analyst Ratings BreakdownLatest PHAR, NAMS, ADPT, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026NAMSNewAmsterdam Pharma BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$58.007/20/2026NAMSNewAmsterdam Pharma Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.007/20/2026NAMSNewAmsterdam Pharma BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/17/2026ADPTAdaptive Biotechnologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026NAMSNewAmsterdam Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026ADPTAdaptive Biotechnologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/13/2026OGNOrganon & Co. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)7/9/2026ADPTAdaptive Biotechnologies Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$18.00 ➝ $20.006/30/2026NAMSNewAmsterdam Pharma Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$47.00 ➝ $51.006/29/2026ADPTAdaptive Biotechnologies GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $22.006/17/2026ADPTAdaptive Biotechnologies BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$276.98M12.87N/AN/A$1.47 per share15.15NAMSNewAmsterdam Pharma$22.50M154.00N/AN/A$5.97 per share4.96OGNOrganon & Co.$6.16B0.58$5.78 per share2.34$2.89 per share4.68PHARPharming Group$376.13M2.37$0.19 per share65.67$3.95 per share3.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$59.50M-$0.33N/AN/AN/A-16.82%-40.06%-16.64%8/4/2026 (Estimated)NAMSNewAmsterdam Pharma-$203.82M-$1.79N/AN/AN/A-943.23%-26.49%-24.37%8/5/2026 (Estimated)OGNOrganon & Co.$187M$0.9314.543.931.263.99%99.95%6.22%8/4/2026 (Estimated)PHARPharming Group$2.85M$0.1678.7919.39N/A3.30%4.64%2.55%7/30/2026 (Estimated)Latest PHAR, NAMS, ADPT, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026NAMSNewAmsterdam Pharma-$0.48N/AN/AN/A$1.88 millionN/A8/4/2026Q2 2026ADPTAdaptive Biotechnologies-$0.1336N/AN/AN/A$65.44 millionN/A8/4/2026Q2 2026OGNOrganon & Co.$0.87N/AN/AN/A$1.57 billionN/A7/30/2026Q2 2026PHARPharming Group$0.0630N/AN/AN/A$99.52 millionN/A5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46-$0.40+$0.06-$0.40$1.75 million$3.04 million5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million5/5/2026Q1 2026ADPTAdaptive Biotechnologies-$0.16-$0.13+$0.03-$0.13$61.03 million$70.87 million4/30/2026Q1 2026OGNOrganon & Co.$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.59%N/A8.60%N/APHARPharming GroupN/AN/AN/AN/AN/ALatest PHAR, NAMS, ADPT, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026OGNOrganon & Co.quarterly$0.020.6%5/11/20265/11/20266/11/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A3.353.22NAMSNewAmsterdam PharmaN/A9.769.76OGNOrganon & Co.9.471.971.42PHARPharming Group0.352.632.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%NAMSNewAmsterdam Pharma89.89%OGNOrganon & Co.77.43%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies5.70%NAMSNewAmsterdam Pharma12.74%OGNOrganon & Co.1.62%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790160.04 million150.92 millionOptionableNAMSNewAmsterdam Pharma4116.90 million102.01 millionOptionableOGNOrganon & Co.10,000262.61 million258.36 millionNot OptionablePHARPharming Group28070.78 million69.31 millionNot OptionablePHAR, NAMS, ADPT, and OGN HeadlinesRecent News About These CompaniesPharming Group (PHAR) to Release Earnings on ThursdayJuly 23 at 4:40 AM | marketbeat.comAnalysts Set Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Target Price at $38.33July 22 at 3:00 AM | defenseworld.netDPharming Group (NASDAQ:PHAR) & Briacell Therap (NASDAQ:BCTX) Head to Head ContrastJuly 20, 2026 | americanbankingnews.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by AnalystsJuly 19, 2026 | marketbeat.comPharming Group to report second quarter and first half 2026 financial results and provide business update on July 30July 16, 2026 | finance.yahoo.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What HappenedJuly 15, 2026 | marketbeat.comPharming Group Posts Strong 2025 Growth, Turns Profitable and Lifts 2026 OutlookJuly 8, 2026 | theglobeandmail.comPharming Group (ENXTAM:PHARM) Stock Gets Fair Value Boost As Joenja Progress Supports Growth CaseJune 28, 2026 | uk.finance.yahoo.comUS FDA accepts Pharming’s supplemental NDA resubmission for Joenja to treat children aged 4 to 11 years with APDSJune 6, 2026 | pharmabiz.comPPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSJune 5, 2026 | markets.businessinsider.comPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSJune 4, 2026 | globenewswire.comPharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New YorkJune 2, 2026 | finance.yahoo.comPharming Group N.V.: Pharming Group announces results of 2026 Annual General Meeting of ShareholdersMay 28, 2026 | finanznachrichten.dePharming Group announces results of 2026 Annual General Meeting of ShareholdersMay 28, 2026 | manilatimes.netMPharming Group N.V. (PHAR) Shareholder/Analyst Call - SlideshowMay 28, 2026 | seekingalpha.comPharming’s Joenja receives European marketing authorization for the treatment of activated PI3K delta syndromeMay 26, 2026 | pharmabiz.comPEuropean Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European UnionMay 22, 2026 | markets.businessinsider.comPharming Group N.V. Recorded A 21% Miss On Revenue: Analysts Are Revisiting Their ModelsMay 10, 2026 | finance.yahoo.comPharming Group (PHAR) Gets a Buy from Canaccord GenuityMay 9, 2026 | theglobeandmail.comPharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026May 7, 2026 | markets.businessinsider.comPharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersMay 7, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 European Stocks to Carry Investors Through the Back Half of 2026By Chris Markoch | July 1, 2026The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsBy Jeffrey Neal Johnson | July 13, 20263 Overlooked Stocks Positioned for the Next Market RotationBy Bridget Bennett | July 13, 2026Vertex’s Crinetics Deal Balances Growth with Integration RiskBy Chris Markoch | July 8, 20263 Medical Device Stocks Giving Investors a Different Healthcare PlayBy Nathan Reiff | July 20, 2026PHAR, NAMS, ADPT, and OGN Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$22.27 -0.04 (-0.18%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$22.43 +0.16 (+0.73%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.NewAmsterdam Pharma NASDAQ:NAMS$29.64 -0.91 (-2.98%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$29.63 -0.01 (-0.03%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Organon & Co. NYSE:OGN$13.52 -0.04 (-0.26%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$13.52 -0.01 (-0.07%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Pharming Group NASDAQ:PHAR$12.60 -0.57 (-4.29%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$12.60 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
